제노레이
Financials
Valuation Metrics
제노레이's Market Cap is ₩498B. At end of 2025 it was ₩605B. Ranked #1746 of 2,436 in KR market (top 72%), #1057 of 1,649 on KOSDAQ (top 64%), #71 of 96 in Health Care Equipment & Services (top 74%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 49.77B KRW | KR#1,746/2,436 Sec#71/96 |
| Revenue | 108.27B KRW | KR#1,351/2,436 Sec#31/96 |
| Net Income | 106.5M KRW | KR#1,497/2,436 Sec#50/96 |
| Total Assets | 136.52B KRW | KR#1,531/2,436 Sec#46/96 |
| Net Assets | 82.60B KRW | KR#1,533/2,436 Sec#45/96 |
| Employees | 358 | KR#674/2,436 Sec#16/96 |
| Value | ||
| P/E | 467.50x | KR#1,498/2,436 Sec#50/96 |
| P/B | 0.60x | KR#1,002/2,436 Sec#17/96 |
| P/S | 0.46x | KR#865/2,436 Sec#7/96 |
| FCF Yield | 7.95% | KR#708/2,436 Sec#14/96 |
| Profitability | ||
| ROE | 0.13% | KR#1,483/2,436 Sec#50/96 |
| ROA | 0.08% | KR#1,478/2,436 Sec#49/96 |
| Op. Margin | -1.75% | KR#1,730/2,436 Sec#54/96 |
| Revenue Growth | 0.90% | KR#1,382/2,436 Sec#63/96 |
| Earnings Growth | -560.20% | KR#1,641/2,436 Sec#55/96 |
| Financial Health | ||
| Debt Ratio | 165.26% | KR#1,381/2,436 Sec#71/96 |
| Total Debt | 26.47B KRW | KR#1,248/2,436 Sec#30/96 |
| FCF | 3.96B KRW | KR#958/2,436 Sec#26/96 |
| Cash | 11.41B KRW | KR#1,598/2,436 Sec#56/96 |
| Current Ratio | 1.94x | KR#986/2,436 Sec#53/96 |
| Dividend | ||
| Div. Yield | 4.39% | KR#370/2,436 Sec#3/96 |
| Div. Growth | -16.67% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | -38.82% | KR#1,808/2,436 Sec#63/96 |
| 1M Return | -0.44% | KR#927/2,436 Sec#44/96 |
| From 52W High | -41.54% | KR#827/2,436 Sec#32/96 |
| 1Y MDD | -45.58% | KR#726/2,436 Sec#21/96 |
| Trading | ||
| Volume | 957 shares | KR#2,378/2,436 Sec#96/96 |
| Foreign Own. | 1.30% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | 15 KRW | KR#1,509/2,436 Sec#50/96 |
| BPS | 6,548 KRW | KR#1,241/2,436 Sec#28/96 |
Company Info
Established in 2001 and listed on KOSDAQ in 2018, the company maintains overseas branches in the United States, Germany, Japan, Türkiye, and China. It researches, develops, manufactures, and sells X-ray diagnostic equipment for hospital and dental medical environments, uniquely operating in both medical and dental sectors domestically. Leveraging its proprietary Complementary Metal-Oxide-Semiconductor Flat Panel Detector (CMOS FPD) sensor development and manufacturing technology, the company achieves cost competitiveness and high quality. It internalizes operations from R&D to sales to meet market demands. Genoray is headquartered in Seongnam-si, Gyeonggi-do.